{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:28:21Z","timestamp":1790173701729,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000070","name":"National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"publisher","award":["R21 EB034465"],"award-info":[{"award-number":["R21 EB034465"]}],"id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000743","name":"Institute of Advanced Legal Studies, School of Advanced Study, University of London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000743","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030618","name":"Institute for Applied Life Sciences, University of Massachusetts Amherst","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030618","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["K22 CA262355"],"award-info":[{"award-number":["K22 CA262355"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.xcrm.2025.102415","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T05:36:28Z","timestamp":1760074588000},"page":"102415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Super-adjuvant nanoparticles for platform cancer vaccination"],"prefix":"10.1016","volume":"6","author":[{"given":"Griffin I.","family":"Kane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiana E.","family":"Naylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellis F.","family":"Lusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan L.","family":"Brassil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Wigglesworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronnie W.","family":"Dinnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda B.","family":"Diaz-Infante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah M.","family":"Whiteman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Lukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohini","family":"Josh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Cerrutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Gallucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8470-7235","authenticated-orcid":false,"given":"Prabhani U.","family":"Atukorale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2025.102415_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/cells12172159","article-title":"Cancer Vaccine Therapeutics: Limitations and Effectiveness-A Literature Review","volume":"12","author":"Kaczmarek","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.xcrm.2025.102415_bib2","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/s43018-022-00418-6","article-title":"Cancer vaccines: the next immunotherapy frontier","volume":"3","author":"Lin","year":"2022","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.xcrm.2025.102415_bib3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13045-022-01247-x","article-title":"Cancer vaccines as promising immuno-therapeutics: platforms and current progress","volume":"15","author":"Liu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2025.102415_bib4","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature12978","article-title":"Structure-based programming of lymph-node targeting in molecular vaccines","volume":"507","author":"Liu","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102415_bib5","article-title":"Lymph node targeting for immunotherapy","volume":"20","author":"Wang","year":"2023","journal-title":"Immunooncol. Technol."},{"key":"10.1016\/j.xcrm.2025.102415_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113914","article-title":"Vaccine delivery systems toward lymph nodes","volume":"179","author":"Ding","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.xcrm.2025.102415_bib7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: from basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2025.102415_bib8","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","article-title":"Vaccine adjuvants: mechanisms and platforms","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.xcrm.2025.102415_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2016.05.001","article-title":"Vaccine technologies: From whole organisms to rationally designed protein assemblies","volume":"120","author":"Karch","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.xcrm.2025.102415_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1105420","article-title":"Designing neoantigen cancer vaccines, trials, and outcomes","volume":"14","author":"Biswas","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2025.102415_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10588","article-title":"Cancer vaccines in the clinic","volume":"9","author":"Janes","year":"2024","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.xcrm.2025.102415_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.627932","article-title":"Cancer Vaccines, Adjuvants, and Delivery Systems","volume":"12","author":"Paston","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2025.102415_bib13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2025.102415_bib14","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12951-023-01977-1","article-title":"Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent advances and future directions","volume":"21","author":"Li","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.xcrm.2025.102415_bib15","article-title":"Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8(+) T cell response","volume":"119","author":"Chen","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2025.102415_bib16","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1021\/acsbiomaterials.1c01274","article-title":"Nanotechnology-Based Approaches to Promote Lymph Node Targeted Delivery of Cancer Vaccines","volume":"8","author":"He","year":"2022","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.xcrm.2025.102415_bib17","article-title":"Engineering approaches for innate immune-mediated tumor microenvironment remodeling","volume":"21","author":"Kane","year":"2024","journal-title":"Immunooncol. Technol."},{"key":"10.1016\/j.xcrm.2025.102415_bib18","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1021\/acs.molpharmaceut.1c00447","article-title":"Lipid-Based Nanoparticles for Delivery of Vaccine Adjuvants and Antigens: Toward Multicomponent Vaccines","volume":"18","author":"Chatzikleanthous","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.xcrm.2025.102415_bib19","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.it.2024.07.007","article-title":"Nanocarrier design for pathogen-inspired innate immune agonist delivery","volume":"45","author":"Kane","year":"2024","journal-title":"Trends Immunol."},{"key":"10.1016\/j.xcrm.2025.102415_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adj9366","article-title":"Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer","volume":"16","author":"Chibaya","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2025.102415_bib21","first-page":"29","article-title":"Polymeric Nanoparticle-Based Vaccine Adjuvants and Delivery Vehicles","volume":"433","author":"Grego","year":"2021","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.xcrm.2025.102415_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119390","article-title":"A TLR9-adjuvanted vaccine formulated into dissolvable microneedle patches or cationic liposomes protects against leishmaniasis after skin or subcutaneous immunization","volume":"586","author":"Lanza","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.xcrm.2025.102415_bib23","doi-asserted-by":"crossref","first-page":"7335","DOI":"10.4049\/jimmunol.176.12.7335","article-title":"Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes","volume":"176","author":"Zaks","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.xcrm.2025.102415_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/mabi.202100133","article-title":"Nanoparticle-Mediated STING Agonist Delivery for Enhanced Cancer Immunotherapy","volume":"21","author":"Zhou","year":"2021","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.xcrm.2025.102415_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002852","article-title":"STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation","volume":"9","author":"Nakamura","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2025.102415_bib26","doi-asserted-by":"crossref","first-page":"5977","DOI":"10.1021\/acs.chemrev.1c00750","article-title":"Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy","volume":"122","author":"Garland","year":"2022","journal-title":"Chem. Rev."},{"key":"10.1016\/j.xcrm.2025.102415_bib27","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jconrel.2017.01.004","article-title":"Encapsulation of two different TLR ligands into liposomes confer protective immunity and prevent tumor development","volume":"247","author":"Bayyurt","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.xcrm.2025.102415_bib28","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.imbio.2017.06.002","article-title":"Effect of TLR ligands co-encapsulated with multiepitopic antigen in nanoliposomes targeted to human DCs via Fc receptor for cancer vaccines","volume":"222","author":"Rueda","year":"2017","journal-title":"Immunobiology"},{"key":"10.1016\/j.xcrm.2025.102415_bib29","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.7150\/thno.22056","article-title":"The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide","volume":"8","author":"Lai","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.xcrm.2025.102415_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd4235","article-title":"TRAF6-IRF5 kinetics, TRIF, and biophysical factors drive synergistic innate responses to particle-mediated MPLA-CpG co-presentation","volume":"7","author":"Pradhan","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.xcrm.2025.102415_bib31","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12951-024-02311-z","article-title":"The quest for nanoparticle-powered vaccines in cancer immunotherapy","volume":"22","author":"Sun","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.xcrm.2025.102415_bib32","first-page":"576","article-title":"Nanoparticle cancer vaccines: Design considerations and recent advances","volume":"15","author":"Liu","year":"2020","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.xcrm.2025.102415_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14205163","article-title":"Neoantigen Vaccines; Clinical Trials, Classes, Indications, Adjuvants and Combinatorial Treatments","volume":"14","author":"Niemi","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.xcrm.2025.102415_bib34","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the development of personalized neoantigen-based therapeutic cancer vaccines","volume":"18","author":"Blass","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102415_bib35","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/14760584.2018.1434000","article-title":"Current challenges for cancer vaccine adjuvant development","volume":"17","author":"Bowen","year":"2018","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.xcrm.2025.102415_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9060668","article-title":"Cancer Vaccines: Promising Therapeutics or an Unattainable Dream","volume":"9","author":"Donninger","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.xcrm.2025.102415_bib37","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102415_bib38","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13045-020-00916-z","article-title":"cGAS-STING, an important pathway in cancer immunotherapy","volume":"13","author":"Jiang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2025.102415_bib39","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1128\/IAI.00022-11","article-title":"The Toll-like receptor 4 agonist monophosphoryl lipid a augments innate host resistance to systemic bacterial infection","volume":"79","author":"Romero","year":"2011","journal-title":"Infect. Immun."},{"key":"10.1016\/j.xcrm.2025.102415_bib40","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.jconrel.2020.11.014","article-title":"Immunostimulatory nanoparticle incorporating two immune agonists for the treatment of pancreatic tumors","volume":"330","author":"Lorkowski","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.xcrm.2025.102415_bib41","doi-asserted-by":"crossref","first-page":"5394","DOI":"10.1158\/0008-5472.CAN-19-0381","article-title":"Nanoparticle Encapsulation of Synergistic Immune Agonists Enables Systemic Codelivery to Tumor Sites and IFNbeta-Driven Antitumor Immunity","volume":"79","author":"Atukorale","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102415_bib42","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1039\/D1NR06577G","article-title":"Dual agonist immunostimulatory nanoparticles combine with PD1 blockade for curative neoadjuvant immunotherapy of aggressive cancers","volume":"14","author":"Atukorale","year":"2022","journal-title":"Nanoscale"},{"key":"10.1016\/j.xcrm.2025.102415_bib43","doi-asserted-by":"crossref","first-page":"6845","DOI":"10.1021\/acsnano.3c04471","article-title":"A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists","volume":"18","author":"Baljon","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.xcrm.2025.102415_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1212476","article-title":"Cancer immunotherapies: advances and bottlenecks","volume":"14","author":"Rui","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2025.102415_bib45","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2303567120","article-title":"Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines","volume":"120","author":"Shepherd","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2025.102415_bib46","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.biocel.2018.03.012","article-title":"Diverse mechanisms of IRF5 action in inflammatory responses","volume":"99","author":"Khoyratty","year":"2018","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.xcrm.2025.102415_bib47","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1084\/jem.20031023","article-title":"LPS-TLR4 signaling to IRF-3\/7 and NF-kappaB involves the toll adapters TRAM and TRIF","volume":"198","author":"Fitzgerald","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.xcrm.2025.102415_bib48","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/ar1469","article-title":"Toll-like receptor downstream signaling","volume":"7","author":"Kawai","year":"2005","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.xcrm.2025.102415_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.612747","article-title":"Optimize Prime\/Boost Vaccine Strategies: Trained Immunity as a New Player in the Game","volume":"12","author":"Palgen","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2025.102415_bib50","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1479-5876-5-20","article-title":"Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL\/T helper peptides in VacciMax","volume":"5","author":"Mansour","year":"2007","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.xcrm.2025.102415_bib51","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/nm.4200","article-title":"Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses","volume":"22","author":"Moynihan","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2025.102415_bib52","first-page":"1065","article-title":"Liposomal gp100 vaccine combined with CpG ODN sensitizes established B16F10 melanoma tumors to anti PD-1 therapy","volume":"23","author":"Yazdani","year":"2020","journal-title":"Iran. J. Basic Med. Sci."},{"key":"10.1016\/j.xcrm.2025.102415_bib53","doi-asserted-by":"crossref","first-page":"6970","DOI":"10.4049\/jimmunol.161.12.6970","article-title":"HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A\/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients","volume":"161","author":"Reynolds","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.xcrm.2025.102415_bib54","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1093\/neuonc\/noaa050","article-title":"Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine","volume":"22","author":"Liu","year":"2020","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.xcrm.2025.102415_bib55","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2025.102415_bib56","doi-asserted-by":"crossref","first-page":"17543","DOI":"10.1073\/pnas.2005794117","article-title":"Tumor cell lysate-loaded immunostimulatory spherical nucleic acids as therapeutics for triple-negative breast cancer","volume":"117","author":"Callmann","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2025.102415_bib57","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1021\/acsabm.9b00183","article-title":"Enhanced Antitumor Immunity Using a Tumor Cell Lysate-Encapsulated CO(2)-Generating Liposomal Carrier System and Photothermal Irradiation","volume":"2","author":"Won","year":"2019","journal-title":"ACS Appl. Bio Mater."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125004884?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125004884?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T23:16:01Z","timestamp":1788563761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379125004884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":57,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2666379125004884"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102415","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Super-adjuvant nanoparticles for platform cancer vaccination","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102415","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102415"}}